823 related articles for article (PubMed ID: 30442276)
81. Learning effects in time trade-off based valuation of EQ-5D health states.
Augestad LA; Rand-Hendriksen K; Kristiansen IS; Stavem K
Value Health; 2012; 15(2):340-5. PubMed ID: 22433766
[TBL] [Abstract][Full Text] [Related]
82. Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents.
Pérez-Sousa MÁ; Olivares PR; Ramírez-Vélez R; Gusi N
Value Health; 2021 Dec; 24(12):1799-1806. PubMed ID: 34838278
[TBL] [Abstract][Full Text] [Related]
83. Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis.
Lin J; Wong CKH; Cheung JPY; Cheung PWH; Luo N
Eur J Health Econ; 2022 Nov; 23(8):1383-1395. PubMed ID: 35122171
[TBL] [Abstract][Full Text] [Related]
84. Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off.
Paveliu MS; Olariu E; Caplescu R; Oluboyede Y; Niculescu-Aron IG; Ernu S; Vale L
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299864
[TBL] [Abstract][Full Text] [Related]
85. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
Hansen TM; Helland Y; Augestad LA; Rand K; Stavem K; Garratt A
BMJ Open; 2020 Jun; 10(6):e034683. PubMed ID: 32532768
[TBL] [Abstract][Full Text] [Related]
86. Time trade-off and ranking exercises are sensitive to different dimensions of EQ-5D health states.
Rand-Hendriksen K; Augestad LA
Value Health; 2012; 15(5):777-82. PubMed ID: 22867789
[TBL] [Abstract][Full Text] [Related]
87. Expect Nothing: The (Lack of) Influence of Subjective Life Expectancy on Valuation of Child Health States.
Lipman SA
Front Health Serv; 2022; 2():803109. PubMed ID: 36925864
[TBL] [Abstract][Full Text] [Related]
88. Quality-of-life valuations of advanced breast cancer by New Zealand women.
Milne RJ; Heaton-Brown KH; Hansen P; Thomas D; Harvey V; Cubitt A
Pharmacoeconomics; 2006; 24(3):281-92. PubMed ID: 16519549
[TBL] [Abstract][Full Text] [Related]
89. Psychometric performance of the Chichewa versions of the EQ-5D-Y-3L and EQ-5D-Y-5L among healthy and sick children and adolescents in Malawi.
Ngwira LG; Maheswaran H; Verstraete J; Petrou S; Niessen L; Smith SC
J Patient Rep Outcomes; 2023 Mar; 7(1):22. PubMed ID: 36892714
[TBL] [Abstract][Full Text] [Related]
90. Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.
Svedbom A; Borgström F; Hernlund E; Ström O; Alekna V; Bianchi ML; Clark P; Curiel MD; Dimai HP; Jürisson M; Uusküla A; Lember M; Kallikorm R; Lesnyak O; McCloskey E; Ershova O; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA
Qual Life Res; 2018 Mar; 27(3):707-716. PubMed ID: 29235059
[TBL] [Abstract][Full Text] [Related]
91. A Qualitative Investigation to Develop an Adapted Version of the EQ-5D-Y-3L for Use in Children Aged 2-4 Years.
Dalziel K; van Heusden A; Sarvananthar J; Jones R; McGregor K; Huang L; Rivero-Arias O; Herdman M; Hiscock H; Devlin N
Value Health; 2023 Oct; 26(10):1525-1534. PubMed ID: 37348834
[TBL] [Abstract][Full Text] [Related]
92. Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries.
Janssen MF; Bonsel GJ; Luo N
Pharmacoeconomics; 2018 Jun; 36(6):675-697. PubMed ID: 29470821
[TBL] [Abstract][Full Text] [Related]
93. Health problems are more common, but less severe when measured using newer EQ-5D versions.
Craig BM; Pickard AS; Lubetkin EI
J Clin Epidemiol; 2014 Jan; 67(1):93-9. PubMed ID: 24075597
[TBL] [Abstract][Full Text] [Related]
94. Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults.
Ferreira LN; Ferreira PL; Ribeiro FP; Pereira LN
Health Qual Life Outcomes; 2016 Jun; 14():89. PubMed ID: 27267761
[TBL] [Abstract][Full Text] [Related]
95. Population-level norm values by EQ-5D-3L in Hungary - a comparison of survey results from 2022 with those from 2000.
Inotai A; Nagy D; Kaló Z; Vokó Z
Qual Life Res; 2024 Jun; ():. PubMed ID: 38839684
[TBL] [Abstract][Full Text] [Related]
96. Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies.
Zrubka Z; Golicki D; Prevolnik-Rupel V; Baji P; Rencz F; Brodszky V; Gulácsi L; Péntek M
Eur J Health Econ; 2019 Jun; 20(Suppl 1):141-154. PubMed ID: 31102159
[TBL] [Abstract][Full Text] [Related]
97. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
98. Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan.
Lee HY; Hung MC; Hu FC; Chang YY; Hsieh CL; Wang JD
J Formos Med Assoc; 2013 Nov; 112(11):699-706. PubMed ID: 24183199
[TBL] [Abstract][Full Text] [Related]
99. Psychometric properties of the EuroQol Five Dimensional Questionnaire (EQ-5D-3L) in caregivers of autistic children.
Khanna R; Jariwala K; Bentley JP
Qual Life Res; 2013 Dec; 22(10):2909-20. PubMed ID: 23615959
[TBL] [Abstract][Full Text] [Related]
100. Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China.
Pei W; Yue S; Zhi-Hao Y; Ruo-Yu Z; Bin W; Nan L
Eur J Health Econ; 2021 Sep; 22(7):1083-1093. PubMed ID: 33893889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
